At a glance
- Originator Boehringer Ingelheim
- Developer Boehringer Ingelheim; Boehringer Ingelheim Pharma KG; Roche Palo Alto LLC
- Class Antiarrhythmics; Antiemetics; Anxiolytics
- Mechanism of Action Serotonin 4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Arrhythmias; Gastrointestinal disorders
Most Recent Events
- 16 Oct 2003 Discontinued for Arrhythmias in Germany (unspecified route)
- 16 Oct 2003 Discontinued for Arrhythmias in Italy (unspecified route)
- 07 Jun 2003 Discontinued - Preclinical for Gastrointestinal disorders in United Kingdom (unspecified route)